Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Interest & Investment Income (2016 - 2026)

Usana Health Sciences has reported Interest & Investment Income over the past 17 years, most recently at $437000.0 for Q2 2026.

  • Quarterly Interest & Investment Income fell 39.56% to $437000.0 in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Apr 2026, down 77.27% year-over-year, with the annual reading at $2.4 million for FY2026, 78.66% down from the prior year.
  • Interest & Investment Income was $437000.0 for Q2 2026 at Usana Health Sciences, down from $495000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $3.1 million in Q3 2024 and troughed at $437000.0 in Q2 2026.
  • The 5-year median for Interest & Investment Income is $1.2 million (2022), against an average of $1.6 million.
  • Year-over-year, Interest & Investment Income skyrocketed 230.46% in 2023 and then tumbled 81.92% in 2026.
  • A 5-year view of Interest & Investment Income shows it stood at $1.5 million in 2022, then skyrocketed by 99.11% to $2.9 million in 2023, then fell by 5.75% to $2.7 million in 2024, then tumbled by 78.89% to $578000.0 in 2025, then decreased by 24.39% to $437000.0 in 2026.
  • Per Business Quant, the three most recent readings for USNA's Interest & Investment Income are $437000.0 (Q2 2026), $495000.0 (Q1 2026), and $578000.0 (Q3 2025).